JP Morgan Chase’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-987,235
| Closed | -$21.4M | – | 5377 |
|
|
2017
Q2 | $21.4M | Buy |
987,235
+596,868
| +153% | +$10.8M | ﹤0.01% | 1399 |
|
|
2017
Q1 | $5.48M | Sell |
390,367
-98,072
| -20% | -$1.61M | ﹤0.01% | 2370 |
|
|
2016
Q4 | $9.16M | Buy |
488,439
+120,612
| +33% | +$2.05M | ﹤0.01% | 1979 |
|
|
2016
Q3 | $6.07M | Buy |
367,827
+266,138
| +262% | +$3.94M | ﹤0.01% | 2112 |
|
|
2016
Q2 | $1.37M | Buy |
101,689
+13,840
| +16% | +$202K | ﹤0.01% | 3014 |
|
|
2016
Q1 | $1.34M | Sell |
87,849
-69,101
| -44% | -$1.08M | ﹤0.01% | 2914 |
|
|
2015
Q4 | $3.12M | Buy |
+156,950
| New | +$2.98M | ﹤0.01% | 2508 |
|
|
2015
Q3 | – | Sell |
-149,833
| Closed | -$3.03M | – | 4214 |
|
|
2015
Q2 | $3.03M | Buy |
149,833
+44,683
| +42% | +$862K | ﹤0.01% | 2671 |
|
|
2015
Q1 | $1.85M | Buy |
+105,150
| New | +$1.79M | ﹤0.01% | 2916 |
|
|
2014
Q4 | – | Sell |
-240,746
| Closed | -$5.31M | – | 4464 |
|
|
2014
Q3 | $5.31M | Sell |
240,746
-2,148
| -0.9% | -$44K | ﹤0.01% | 2337 |
|
|
2014
Q2 | $4.89M | Buy |
242,894
+6,817
| +3% | +$115K | ﹤0.01% | 2080 |
|
|
2014
Q1 | $4.39M | Sell |
236,077
-117,133
| -33% | -$1.61M | ﹤0.01% | 2160 |
|
|
2013
Q4 | $3.56M | Buy |
353,210
+315,318
| +832% | +$3.81M | ﹤0.01% | 2386 |
|
|
2013
Q3 | $488K | Buy |
37,892
+17,539
| +86% | +$216K | ﹤0.01% | 3644 |
|
|
2013
Q2 | $242K | Buy |
+20,353
| New | +$220K | ﹤0.01% | 3910 |
|
Other funds holding AMRI
JP Morgan Chase's AMRI Position: Q3 2017 in Review
JP Morgan Chase sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 987,235 shares — an estimated $21.4M sold.
JP Morgan Chase first reported a position in AMRI in Q2 2013 and held it in 15 quarters. The position peaked at $21.4M in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- JP Morgan Chase reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- JP Morgan Chase sold 987,235 Albany Molecular Research Inc shares in Q3 2017, an estimated $21.4M.
- JP Morgan Chase first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 15 quarters.
- JP Morgan Chase's Albany Molecular Research Inc position peaked at $21.4M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on JP Morgan Chase's 13F filing for Q3 2017, filed 9 Nov 2017.